Glycine (JP14/USP)
Glycine (JP14/USP) Brand names, Glycine (JP14/USP) Analogs
Glycine (JP14/USP) Brand Names Mixture
- No information avaliable
Glycine (JP14/USP) Chemical_Formula
C2H5N1O2
Glycine (JP14/USP) RX_link
No information avaliable
Glycine (JP14/USP) fda sheet
Glycine (JP14/USP) msds (material safety sheet)
Glycine (JP14/USP) Synthesis Reference
No information avaliable
Glycine (JP14/USP) Molecular Weight
75.067 g/mol
Glycine (JP14/USP) Melting Point
240 oC
Glycine (JP14/USP) H2O Solubility
No information avaliable
Glycine (JP14/USP) State
Solid, white powder
Glycine (JP14/USP) LogP
-3.415
Glycine (JP14/USP) Dosage Forms
Capsules, Irrigation solution, powder and tablets.
Glycine (JP14/USP) Indication
Supplemental glycine may have antispastic activity. Very early findings suggest it may also have antipsychotic activity as well as antioxidant and anti-inflammatory activities.
Glycine (JP14/USP) Pharmacology
Helps trigger the release of oxygen to the energy requiring cell-making process; Important in the manufacturing of hormones responsible for a strong immune system.
Glycine (JP14/USP) Absorption
Absorbed from the small intestine via an active transport mechanism.
Glycine (JP14/USP) side effects and Toxicity
ORL-RAT LD50 7930 mg kg-1, SCU-RAT LD50 5200 mg kg-1, IVN-RAT LD50 2600 mg kg-1, ORL-MUS LD50 4920 mg kg-1; Doses of 1 gram daily are very well tolerated. Mild gastrointestinal symptoms are infrequently noted. In one study doses of 90 grams daily were also well tole.
Glycine (JP14/USP) Patient Information
Glycine supplementation should be avoided by pregnant women and nursing mothers. Because of some conversion of glycine to ammonia, those with hepatic impairment should avoid glycine supplementation unless prescribed.
Glycine (JP14/USP) Organisms Affected
Humans and other mammals
